The Swiss maker of pharmaceuticals, surgical products and products to treat eye disorders, which is being taken over by Novartis, has reported global sales of $1,536.4 million for the first quarter, up by 16.2 percent over last year. Excluding foreign currency effects, this was an increase of 9.4 percent. Alcon ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
To continue reading this article register now.